Arkolith/Insider Trading/PTGX/Form 4/A

Patel Dinesh V PH D

President and CEO, DirectorProtagonist Therapeutics, Inc (PTGX) · full profile →Form 4/A · filed May 14, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$7.5M
Net Open-Market Flow
-$7.5M
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 12, 2026Option exercise(M)75K$21.58$1.6M598K
May 12, 2026Sell(S)75K$100.12$7.5M523K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
May 12, 2026Option exercise(M)75K—$0225K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4/A filing (accession 0001104659-26-061476) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4/A XML